Inovio Licenses Electroporation Delivery Technology to ABL
Posted on: Tuesday, 27 May 2008, 09:01 CDT
Inovio Biomedical has entered into a license agreement with Advanced BioScience Laboratories, so that ABL may provide advanced electroporation delivery of DNA vaccines for its research uses.
The license will permit Advanced BioScience Laboratories (ABL), based in Kensington, Maryland, to conduct certain internal research on DNA vaccines delivered using electroporation and to offer electroporation delivery of DNA vaccines as a service for its research customers. Inovio will receive a royalty on such services.
Avtar Dhillon, president and CEO of Inovio, said: "We believe this license may help enable the early development of a number of vaccines designed to elicit strong T-cell responses, which are thought to be needed to control a number of chronic infectious diseases, such as HIV and cancer."
Source: Datamonitor
Related Articles
- Inovio Biomedical Achieves 75% Complete Response Rate in Preclinical Testing of DNA-Based Cancer Vaccine Using Its Electroporation DNA Delivery System
- Advanced Cancer Therapeutics Licenses Technology to Develop Human Papillomavirus (HPV) Vaccine
- SurModics and Merck Enter Ophthalmic License and Research Collaboration Agreement
- Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology
- Inovio Biomedical Highlights Enhanced DNA Vaccine Potency With Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
- Kimball Genetics, Inc. Launches the Warfarin Sensitivity DNA Test for Research
- Euroscreen and Medarex Announce License and Research Service Agreement
- Landec Corporation and Air Products Announce Exclusive License and Research and Development Agreement
- Generex Biotechnology to Present Its Avian Influenza Vaccine Program at DNA Forum in London
- Targacept and AstraZeneca Announce Global License and Research Collaboration Agreement
 |
 |
User Comments (0)
RSS Feeds